Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

Rhea-AI Summary

Exelixis, Inc. (NASDAQ: EXEL) has announced its participation in two major investor conferences in February 2023. The first is the Guggenheim Healthcare Talks Oncology Day, taking place on February 9 at 11:20 am ET in New York. The second conference is the SVB Securities Global Biopharma Conference, with a virtual presentation scheduled for February 15 at 2:20 pm ET.

Investors can access the webcasts via www.exelixis.com. Replays will be available for 30 days after the event. Exelixis focuses on innovative cancer treatments and aims to bring hope to patients through advanced therapies.

– Presentations to be webcast on www.exelixis.com –

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in February:

• Guggenheim Healthcare Talks Oncology Day 2023: Exelixis is scheduled to present at 11:20 am ET / 8:20 am PT on Thursday, February 9 in New York.
• SVB Securities Global Biopharma Conference: Exelixis is scheduled to present virtually at 2:20 pm ET / 11:20 am PT on Wednesday, February 15.

To access the webcast links, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentations to ensure adequate time for any software download that may be required to listen to the webcasts. Replays will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX^® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on Twitter, like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005807/en/

Investors Contact:

Varant Shirvanian

Associate Director, Investor Relations

Exelixis, Inc.

650-837-7917

vshirvanian@exelixis.com

Media Contact:

Hal Mackins

For Exelixis, Inc.

415-994-0040

hal@torchcommunications.com

Source: Exelixis, Inc.

FAQ

When is Exelixis scheduled to present at the Guggenheim Healthcare Talks Oncology Day?

Exelixis is scheduled to present at the Guggenheim Healthcare Talks Oncology Day on February 9, 2023, at 11:20 am ET.

What time is Exelixis's presentation at the SVB Securities Global Biopharma Conference?

Exelixis is set to present virtually at the SVB Securities Global Biopharma Conference on February 15, 2023, at 2:20 pm ET.

Where can I access the webcasts of Exelixis's presentations?

You can access the webcasts of Exelixis's presentations on their official website, www.exelixis.com, under the News & Events section.

How long will the replays of Exelixis's presentations be available?

Replays of Exelixis's presentations will be available for 30 days after the live event.

What is the focus of Exelixis as a company?

Exelixis is focused on innovating next-generation medicines and treatment regimens in the field of oncology.